Protocol for the economic evaluation of the China Salt Substitute and Stroke Study (SSaSS)

Introduction Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. Reducing dietary salt consumption is a potentially cost-effective way to reduce blood pressure and the burden of CVD. To date, economic evidence has focused on sodium reduction in food industry or p...

Full description

Bibliographic Details
Main Authors: Lei Si, Maoyi Tian, Yishu Liu, Xinyi Zhang, Yangfeng Wu, Jie Yu, Jixin Sun, Yi Zhao, Liping Huang, Xiangxian Feng, Bo Zhou, Xuejun Yin, Lijing Yan, Ruijuan Zhang, Zhixin Hao, Jingpu Shi, Jianxin Zhang, Yuhong Zhang, Zhifang Li, Yan Yu, Ka-Chun Li, Nicole Li, Darwin Labarthe
Format: Article
Language:English
Published: BMJ Publishing Group 2021-07-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/11/7/e045929.full
id doaj-6f6aa281f25948719763dfea0c4a6691
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Lei Si
Maoyi Tian
Yishu Liu
Xinyi Zhang
Yangfeng Wu
Jie Yu
Jixin Sun
Yi Zhao
Liping Huang
Xiangxian Feng
Bo Zhou
Xuejun Yin
Lijing Yan
Ruijuan Zhang
Zhixin Hao
Jingpu Shi
Jianxin Zhang
Yuhong Zhang
Zhifang Li
Yan Yu
Ka-Chun Li
Nicole Li
Darwin Labarthe
spellingShingle Lei Si
Maoyi Tian
Yishu Liu
Xinyi Zhang
Yangfeng Wu
Jie Yu
Jixin Sun
Yi Zhao
Liping Huang
Xiangxian Feng
Bo Zhou
Xuejun Yin
Lijing Yan
Ruijuan Zhang
Zhixin Hao
Jingpu Shi
Jianxin Zhang
Yuhong Zhang
Zhifang Li
Yan Yu
Ka-Chun Li
Nicole Li
Darwin Labarthe
Protocol for the economic evaluation of the China Salt Substitute and Stroke Study (SSaSS)
BMJ Open
author_facet Lei Si
Maoyi Tian
Yishu Liu
Xinyi Zhang
Yangfeng Wu
Jie Yu
Jixin Sun
Yi Zhao
Liping Huang
Xiangxian Feng
Bo Zhou
Xuejun Yin
Lijing Yan
Ruijuan Zhang
Zhixin Hao
Jingpu Shi
Jianxin Zhang
Yuhong Zhang
Zhifang Li
Yan Yu
Ka-Chun Li
Nicole Li
Darwin Labarthe
author_sort Lei Si
title Protocol for the economic evaluation of the China Salt Substitute and Stroke Study (SSaSS)
title_short Protocol for the economic evaluation of the China Salt Substitute and Stroke Study (SSaSS)
title_full Protocol for the economic evaluation of the China Salt Substitute and Stroke Study (SSaSS)
title_fullStr Protocol for the economic evaluation of the China Salt Substitute and Stroke Study (SSaSS)
title_full_unstemmed Protocol for the economic evaluation of the China Salt Substitute and Stroke Study (SSaSS)
title_sort protocol for the economic evaluation of the china salt substitute and stroke study (ssass)
publisher BMJ Publishing Group
series BMJ Open
issn 2044-6055
publishDate 2021-07-01
description Introduction Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. Reducing dietary salt consumption is a potentially cost-effective way to reduce blood pressure and the burden of CVD. To date, economic evidence has focused on sodium reduction in food industry or processed food with blood pressure as the primary outcome. This study protocol describes the planned within-trial economic evaluation of a low-sodium salt substitute intervention designed to reduce the risk of stroke in China.Methods and analyses The economic evaluation will be conducted alongside the Salt Substitute and Stroke Study: a 5-year large scale, cluster randomised controlled trial. The outcomes of interest are quality of life measured using the EuroQol-5-Dimensions and major adverse cardiovascular events. Costs will be estimated from a healthcare system perspective and will be sought from the routinely collected data available within the New Rural Cooperative Medical Scheme. Cost-effectiveness and cost-utility analyses will be conducted, resulting in the incremental cost-effectiveness ratio expressed as cost per cardiovascular event averted and cost per quality-adjusted life year gained, respectively.Ethics and dissemination The trial received ethics approval from the University of Sydney Ethics Committee (2013/888) and Peking University Institutional Review Board (IRB00001052-13069). Informed consent was obtained from each study participant. Findings of the economic evaluation will be published in a peer-reviewed journal and presented at international conferences.Trial registration number ClinicalTrials.gov Registry (NCT02092090).
url https://bmjopen.bmj.com/content/11/7/e045929.full
work_keys_str_mv AT leisi protocolfortheeconomicevaluationofthechinasaltsubstituteandstrokestudyssass
AT maoyitian protocolfortheeconomicevaluationofthechinasaltsubstituteandstrokestudyssass
AT yishuliu protocolfortheeconomicevaluationofthechinasaltsubstituteandstrokestudyssass
AT xinyizhang protocolfortheeconomicevaluationofthechinasaltsubstituteandstrokestudyssass
AT yangfengwu protocolfortheeconomicevaluationofthechinasaltsubstituteandstrokestudyssass
AT jieyu protocolfortheeconomicevaluationofthechinasaltsubstituteandstrokestudyssass
AT jixinsun protocolfortheeconomicevaluationofthechinasaltsubstituteandstrokestudyssass
AT yizhao protocolfortheeconomicevaluationofthechinasaltsubstituteandstrokestudyssass
AT lipinghuang protocolfortheeconomicevaluationofthechinasaltsubstituteandstrokestudyssass
AT xiangxianfeng protocolfortheeconomicevaluationofthechinasaltsubstituteandstrokestudyssass
AT bozhou protocolfortheeconomicevaluationofthechinasaltsubstituteandstrokestudyssass
AT xuejunyin protocolfortheeconomicevaluationofthechinasaltsubstituteandstrokestudyssass
AT lijingyan protocolfortheeconomicevaluationofthechinasaltsubstituteandstrokestudyssass
AT ruijuanzhang protocolfortheeconomicevaluationofthechinasaltsubstituteandstrokestudyssass
AT zhixinhao protocolfortheeconomicevaluationofthechinasaltsubstituteandstrokestudyssass
AT jingpushi protocolfortheeconomicevaluationofthechinasaltsubstituteandstrokestudyssass
AT jianxinzhang protocolfortheeconomicevaluationofthechinasaltsubstituteandstrokestudyssass
AT yuhongzhang protocolfortheeconomicevaluationofthechinasaltsubstituteandstrokestudyssass
AT zhifangli protocolfortheeconomicevaluationofthechinasaltsubstituteandstrokestudyssass
AT yanyu protocolfortheeconomicevaluationofthechinasaltsubstituteandstrokestudyssass
AT kachunli protocolfortheeconomicevaluationofthechinasaltsubstituteandstrokestudyssass
AT nicoleli protocolfortheeconomicevaluationofthechinasaltsubstituteandstrokestudyssass
AT darwinlabarthe protocolfortheeconomicevaluationofthechinasaltsubstituteandstrokestudyssass
_version_ 1721216951133405184
spelling doaj-6f6aa281f25948719763dfea0c4a66912021-08-07T16:33:07ZengBMJ Publishing GroupBMJ Open2044-60552021-07-0111710.1136/bmjopen-2020-045929Protocol for the economic evaluation of the China Salt Substitute and Stroke Study (SSaSS)Lei Si0Maoyi Tian1Yishu Liu2Xinyi Zhang3Yangfeng Wu4Jie Yu5Jixin Sun6Yi Zhao7Liping Huang8Xiangxian Feng9Bo Zhou10Xuejun Yin11Lijing Yan12Ruijuan Zhang13Zhixin Hao14Jingpu Shi15Jianxin Zhang16Yuhong Zhang17Zhifang Li18Yan Yu19Ka-Chun Li20Nicole Li21Darwin Labarthe226 The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia 1 The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia 3 The George Institute for Global Health at Peking University Health Science Center, Beijing, China 1 Cancer Research Center of Lyon, UMR INSERM 1052, Lyon, France 8 Clinical Research Institute and School of Public Health, Peking University, Beijing, Beijing, China Department of Emergency, Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Shanghai, China8 Hebei Provincial Center for Disease Control and Prevention, Shijiazhuang, China 1 Department of Gastroenterology, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China The George Institute for Global Health, UNSW, Sydney, New South Wales, AustraliaChangzhi Medical College, Changzhi, China5 Respiratory Department, First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China 1 The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia Global Health Research Center, Duke Kunshan University, Jiangsu, ChinaSchool of Public Health, Xian Jiaotong University, Xi'an, Shaanxi, ChinaThe George Institute for Global Health at Peking University Health Science Center, Beijing, ChinaDepartment of Evidence-based Medicine, First Hospital of China Medical University, Shenyang, ChinaDepartment of Non-communicable Diseases, Center for Disease Control of Heibei, Shijiazhuang, ChinaSchool of Public Health, Ningxia Medical University, Yinchuan, ChinaSchool of Preventive Medicine, Changzhi Medical College, Changzhi, ChinaSchool of Public Health, Xi’an Jiaotong University Health Science Center, Xi'an, ChinaThe George Institute for Global Health, University of New South Wales, Sydney, New South Wales, AustraliaGeorge Clinical, Sydney, New South Wales, AustraliaFeinberg School of Medicine, Northwestern University, Chicago, Illinois, USAIntroduction Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. Reducing dietary salt consumption is a potentially cost-effective way to reduce blood pressure and the burden of CVD. To date, economic evidence has focused on sodium reduction in food industry or processed food with blood pressure as the primary outcome. This study protocol describes the planned within-trial economic evaluation of a low-sodium salt substitute intervention designed to reduce the risk of stroke in China.Methods and analyses The economic evaluation will be conducted alongside the Salt Substitute and Stroke Study: a 5-year large scale, cluster randomised controlled trial. The outcomes of interest are quality of life measured using the EuroQol-5-Dimensions and major adverse cardiovascular events. Costs will be estimated from a healthcare system perspective and will be sought from the routinely collected data available within the New Rural Cooperative Medical Scheme. Cost-effectiveness and cost-utility analyses will be conducted, resulting in the incremental cost-effectiveness ratio expressed as cost per cardiovascular event averted and cost per quality-adjusted life year gained, respectively.Ethics and dissemination The trial received ethics approval from the University of Sydney Ethics Committee (2013/888) and Peking University Institutional Review Board (IRB00001052-13069). Informed consent was obtained from each study participant. Findings of the economic evaluation will be published in a peer-reviewed journal and presented at international conferences.Trial registration number ClinicalTrials.gov Registry (NCT02092090).https://bmjopen.bmj.com/content/11/7/e045929.full